BAMCO Inc
ESPR

BAMCO Inc’s Esperion Therapeutics ESPR Stock Holding History

BAMCO Inc’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-373,500
Closed -$10.5M – 409
2021
Q1 		$10.5M Hold
373,500
– – 0.03% 286
2020
Q4 		$9.71M Buy
373,500
+40,000
+12% +$1.2M 0.02% 271
2020
Q3 		$12.4M Buy
333,500
+45,000
+16% +$1.78M 0.04% 232
2020
Q2 		$14.8M Buy
288,500
+100,000
+53% +$4.18M 0.05% 191
2020
Q1 		$5.94M Hold
188,500
– – 0.03% 226
2019
Q4 		$11.2M Hold
188,500
– – 0.04% 206
2019
Q3 		$6.91M Hold
188,500
– – 0.03% 234
2019
Q2 		$8.77M Buy
188,500
+5,000
+3% +$235K 0.04% 228
2019
Q1 		$7.37M Buy
183,500
+83,500
+84% +$3.75M 0.03% 226
2018
Q4 		$4.6M Hold
100,000
– – 0.02% 244
2018
Q3 		$4.44M Buy
100,000
+84,100
+529% +$3.86M 0.02% 257
2018
Q2 		$623K Sell
15,900
-9,000
-36% -$455K ﹤0.01% 313
2018
Q1 		$1.8M Buy
24,900
+12,000
+93% +$881K 0.01% 280
2017
Q4 		$849K Buy
+12,900
New +$695K ﹤0.01% 298
2016
Q1 		– Sell
-12,200
Closed -$272K – 304
2015
Q4 		$272K Hold
12,200
– – ﹤0.01% 302
2015
Q3 		$288K Hold
12,200
– – ﹤0.01% 332
2015
Q2 		$997K Sell
12,200
-12,300
-50% -$1.2M ﹤0.01% 327
2015
Q1 		$2.27M Sell
24,500
-10,700
-30% -$691K 0.01% 294
2014
Q4 		$1.42M Buy
35,200
+11,200
+47% +$343K 0.01% 306
2014
Q3 		$587K Buy
+24,000
New +$381K ﹤0.01% 337

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BAMCO Inc's ESPR Position: Q2 2021 in Review

BAMCO Inc sold out of Esperion Therapeutics (ESPR) in Q2 2021, closing a stake of 373,500 shares — an estimated $10.5M sold.

BAMCO Inc first reported a position in ESPR in Q3 2014 and held it in 20 quarters. The position peaked at $14.8M in Q2 2020. 142 funds tracked by Wall St. Rank hold ESPR as of Q2 2021.

  • BAMCO Inc reported no remaining Esperion Therapeutics position as of Q2 2021 after selling out during the quarter.
  • BAMCO Inc sold 373,500 Esperion Therapeutics shares in Q2 2021, an estimated $10.5M.
  • BAMCO Inc first reported a position in Esperion Therapeutics in Q3 2014 and held it in 20 quarters.
  • BAMCO Inc's Esperion Therapeutics position peaked at $14.8M in Q2 2020.
  • 142 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2021.

Based on BAMCO Inc's 13F filing for Q2 2021, filed 13 Aug 2021.